MedTrace Logo

Use of Topical Euphrasia, a Homeopathic Remedy in Ophthalmology

NCT02416128 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2023-10-16

No results posted yet for this study

Summary

The investigators plan to use an herbal eye drop, Euphrasia, aka Eyebright, for post-operative inflammation for Peripheral Laser Iridotomy for the treatment of narrow angle glaucoma. A peripheral Laser Iridotomy is a simple laser procedure with few complications if the patient follows the post-operative instructions. In this procedure, a blue-green Argon laser is used to create an orifice in the iris to open the angle by allowing the aqueous from behind the iris to enter the anterior chamber. Rarely the procedure needs to be repeated. The main complications from this surgery are postoperative inflammation, bleeding, and postoperative pressure spikes.

The investigators will be using Weleda's Euphrasia D3 eye drops. The investigators plan to do a double blinded randomized control trial to objectively measure ocular inflammation in the same process that was used for the steroid eye drops that are currently out on the market. Some patients will be receiving steroids, prednisolone acetate, others, the herbal eye drop.

Conditions

  • Iritis

Interventions

DRUG

Euphrasia

1 drop in the treated eye QID X 10 days

DRUG

Prednisolone acetate

1 drop in the treated eye QID X 10 days

Sponsors & Collaborators

  • Nova Southeastern University

    collaborator OTHER

  • Larkin Community Hospital

    lead OTHER

Principal Investigators

  • Austin Bach, DO · Larkin Community Hospital/Nova Southeastern University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2016-03-25
Completion
2016-03-25

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02416128 on ClinicalTrials.gov